MannKind Corp. Stock
€3.36
Your prediction
Financial data and news for MannKind
sharewise wants to provide you with the best news and tools for MannKind, so we directly link to the best financial data sources.
Financials
News
MannKind’s Inhaled IPF Drug Clears Phase 1b Safety Hurdle, Phase 2 Underway
Key Points
- Interested in MannKind Corporation? Here are five stocks we like better.
- MannKind’s Phase 1b trial met its short-term safety and tolerability objective in 27 IPF patients, with no
MannKind Wins FDA Approval for Furoscix ReadyFlow, Secures $50M PIPE
Key Points
- Interested in MannKind Corporation? Here are five stocks we like better.
- MannKind received FDA approval for Furoscix ReadyFlow, an auto-injector that delivers an 80 mg dose of
MannKind Wins FDA Approval for Afrezza in Children, Opening Pediatric Diabetes Market
Key Points
- Interested in MannKind Corporation? Here are five stocks we like better.
- MannKind won FDA approval for Afrezza in pediatric patients ages 6 and older, expanding its inhaled mealtime
What This MannKind Filing Reveals About Three Years of Underperformance
Sanjay R. Singh, EVP Technical Operations at MannKind Corporation (NASDAQ:MNKD), disposed of 46,795 shares of common stock on July 15, 2026, as disclosed in a recent SEC Form 4 filing.
Transaction
What This MannKind Director Sale Signals With $32.7 Million in Quarterly Royalties Revenue Potentially at Risk
Director Steven B. Binder disclosed a disposition of 76,880 shares of MannKind Corporation (NASDAQ:MNKD) at $4.07 per share in transactions completed on July 15, 2026, and July 17, 2026, according
What This MannKind Sale Signals With Tyvaso Royalties at $32.7 Million
David Thomson, EVP General Counsel & Secretary of MannKind Corporation (NASDAQ:MNKD), reported a sale of 123,000 shares of common stock between July 15 and July 17, 2026, according to a recent SEC
Why This MannKind Insider Stock Sale Matters Less Than a 9% Royalty at Risk
Stuart A. Tross, chief people & workplace officer of MannKind Corporation (NASDAQ:MNKD), reported the disposition of 65,808 shares at $4.09 per share on July 15, 2026, according to an SEC Form 4
Is MannKind a Stock to Sell After Its CEO Let Go of 363,200 Shares?
Michael Castagna, Chief Executive Officer of MannKind Corporation (NASDAQ:MNKD), disposed of 363,200 shares of common stock on July 15, 2026, according to a recent SEC Form 4 filing.
Transaction
Why MannKind Stock Tumbled on Thursday
MannKind (NASDAQ: MNKD) was a stock to avoid on the second-to-last trading day of the week. Investors eagerly sold out of the commercial-stage biotech's equity, as they clearly felt its latest